GYRE at a glance
GYRE THERAPEUTICS, INC. (GYRE, SEC CIK 1124105) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 1, 2026 and Form 4 insider filings as recently as August 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), GYRE THERAPEUTICS, INC. (GYRE) reported revenue of $116.6 million (up 10.2% from FY2024) and net income of $9.9 million. Diluted EPS was $0.02.
- As of June 30, 2026, 16 institutional investment managers tracked by SignalX reported holding GYRE THERAPEUTICS, INC. (GYRE) shares worth $17.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Ye Weiguo on June 18, 2026 of 3,000 shares at $6.35 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $116.6M
- +10.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 16 funds
- $17.9M · +1 vs prior quarter
- Latest 8-K
- Sep 1, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $29.105M, down 2% YoY from $29.734M
- Net loss $14.270M vs $2.237M; operating loss $14.363M vs $2.240M
- Best segment: no segment revenue breakdown disclosed
- Cash $43.3M vs $49.2M at December 31, 2025; Cullgen acquired for approximately $300M in stock
- Near-term priorities: pipeline review, capital allocation, and program prioritization following Cullgen acquisition
Risk Factors
- New risk: pledged GNI Parties shares securing JPY 20 billion loan, triggered by GNI Japan financing Ayumi Pharmaceutical acquisition
- Most material update: foreclosure risk following loan maturity on July 1, 2027 and potential default
- Market risk: thin trading and concentrated ownership could amplify price declines from substantial share sales
- Governance risk: foreclosure could change control and end controlled-company status under Nasdaq rules
AI summary of the GYRE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Item 7.01 indicates Regulation FD disclosure, but the provided text contains only an incorporation-by-reference disclaimer
- No substantive business, financial, or investor-relevant information appears in the excerpt
Item EX-99.1: Item EX-99.1
- Corporate presentation outlines Gyre’s China-enabled, capital-efficient pipeline across oncology, autoimmune disease, pain and fibrosis
- ETUARY FY26 revenue guidance of $100.5M-$111M provides commercial funding for early-stage research and development
Item 7.01: Regulation FD Disclosure
- Standard Reg FD disclosure disclaimer limiting Exchange Act Section 18 liability
- 8-K content excluded from automatic incorporation into other Exchange Act or Securities Act filings
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Results furnished in Exhibit 99.1, including management commentary and other disclosed matters
Item EX-99.1: Item EX-99.1
- Q2 revenue $29.1M, down 2%; ETUARY sales rose to $28.0M while Etorel and Contiva declined under centralized procurement
- Full-year 2026 revenue guidance maintained at $100.5M-$111.0M despite Astellas collaboration revenue ending in March
AI summaries of GYRE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GYRE
Don't miss the next GYRE filing
- Alerts as it files. A push when GYRE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GYRE, by share count.
- Ask anything. An AI agent that reads every GYRE filing and answers with sources.
GYRE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Weston Claire | A | Aug 3, 2026 | 40,000 | - |
| Kirkby Maxwell | A | Aug 3, 2026 | 40,000 | - |
| Ye Weiguo | Sell | Jun 18, 2026 | 3,000 | $6.35 |
| Ye Weiguo | M | Jun 18, 2026 | 3,000 | - |
| Ye Weiguo | M | Jun 18, 2026 | 3,000 | $0.75 |
| Ye Weiguo | M | Jun 11, 2026 | 2,800 | - |
| Ye Weiguo | Sell | Jun 11, 2026 | 2,800 | $6.17 |
| Ye Weiguo | M | Jun 11, 2026 | 2,800 | $0.75 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $105.8M | $116.6M |
| Gross Profit | - | $101.9M | - |
| Operating Income | - | $16.2M | $11.5M |
| Net Income | - | $17.9M | $9.9M |
| Gross Margin | - | 96.3% | - |
| Op. Margin | - | 15.3% | 9.9% |
| Net Margin | - | 16.9% | 8.5% |
| Balance Sheet | |||
| Total Assets | $116.5M | $125.4M | $166.1M |
| Equity | -$15.8M | $63.3M | $106.0M |
| ROE | - | 28.3% | 9.3% |
| Per Share | |||
| EPS | $-1.41 | $0.05 | $0.02 |
| Cash Flow | |||
| Operating CF | - | -$3.6M | $1.0M |
| CapEx | - | $2.3M | $1.2M |
Source: XBRL data in GYRE THERAPEUTICS, INC. (GYRE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate GYRE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 16 | $17.9M |
| Q1 2026 | 15 | $16.4M |
| Q4 2025 | 13 | $17.1M |
| Q3 2025 | 13 | $16.6M |
| Q2 2025 | 12 | $17.7M |
| Q1 2025 | 11 | $10.8M |
| Q4 2024 | 6 | $6.9M |
| Q3 2024 | 4 | $2.7M |
- BlackRock+235.3K (+31%)
- Vanguard Portfolio Management LLC+54.1K (+78%)
- Northern Trust+35.7K (+27%)
- Morgan Stanley+33.0K (+382%)
- State Street Corp+29.1K (+13%)
- Vanguard Capital Management LLC−107.3K (-11%)
- FMR LLC (Fidelity)−3.7K (-20%)
- Millennium Management+18.5K
- T. Rowe Price Group+15.0K
- U.S. Bancorp−98
Source: 13F-HR filings on SEC EDGAR (aggregated from 90 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GYRE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GYRE SEC filings: frequently asked questions
Which institutions hold GYRE stock?
As of June 30, 2026, the largest GYRE THERAPEUTICS, INC. (GYRE) holders among the 13F filers tracked by SignalX were BlackRock ($6.5 million), Vanguard Capital Management LLC ($5.8 million), State Street Corp ($1.6 million), Northern Trust ($1.1 million), Vanguard Portfolio Management LLC ($817,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GYRE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), GYRE THERAPEUTICS, INC. (GYRE) reported revenue of $116.6 million (up 10.2% from FY2024) and net income of $9.9 million. Diluted EPS was $0.02. The figures come from the XBRL data in the 10-K.
What did GYRE report in its latest 8-K?
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K on September 1, 2026 reporting Item 7.01 (Regulation FD Disclosure). Item 7.01 indicates Regulation FD disclosure, but the provided text contains only an incorporation-by-reference disclaimer.
What are the latest GYRE SEC filings?
GYRE THERAPEUTICS, INC. (GYRE) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 1, 2026 and a Form 4 insider filing on August 4, 2026.
What is GYRE's SEC CIK number?
GYRE THERAPEUTICS, INC. (GYRE)'s SEC Central Index Key (CIK) is 1124105. EDGAR lists every GYRE filing under that number.
Ask anything about GYRE
The research agent reads GYRE's filings, financials, insider trades and 13F holders, then answers with sources.